Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil

被引:34
|
作者
de Melo, Andrea Barbosa [1 ]
da Silva, Maria da Paz C. [2 ]
Magalhaes, Maria Cecilia F. [1 ]
Vega Gonzales Gil, Laura Helena [1 ]
Freese de Carvalho, Eduardo M. [5 ]
Braga-Neto, Ulisses M. [3 ]
Bertani, Giovani Rota [2 ]
Marques, Ernesto T. A., Jr. [1 ,4 ]
Cordeiro, Marli Tenorio [1 ,6 ]
机构
[1] Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil
[2] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil
[3] Texas A&M Univ, Dept Elect Engn, College Stn, TX 77843 USA
[4] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA
[5] Aggeu Magalhaes Res Ctr, Dept Saude Colet, Recife, PE, Brazil
[6] Secretaria Saude Estado Pernambuco, Telephone & Cent Lab Publ Hlth, Recife, PE, Brazil
来源
基金
美国国家科学基金会;
关键词
SERIOUS ADVERSE EVENTS; HEMAGGLUTINATION-INHIBITION; IMMUNOFLUORESCENCE ASSAY; IGG ANTIBODIES; UNITED-STATES; MAC-ELISA; DENGUE; VIRUS; IMMUNOGENICITY; NEUTRALIZATION;
D O I
10.4269/ajtmh.2011.10-0496
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).
引用
收藏
页码:739 / 747
页数:9
相关论文
共 50 条
  • [1] Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD
    Gandolfi, Flora de Andrade
    Estofolete, Cassia Fernanda
    Wakai, Marcia Catelan
    Negri, Andreia Francesli
    Barcelos, Michela Dias
    Vasilakis, Nikos
    Nogueira, Mauricio Lacerda
    [J]. VACCINES, 2023, 11 (02)
  • [2] Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys
    Marchevsky, RS
    Freire, MS
    Coutinho, ESF
    Galler, R
    [J]. VIROLOGY, 2003, 316 (01) : 55 - 63
  • [3] Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases
    Vasconcelos, PFC
    Luna, EJ
    Galler, R
    Silva, LJ
    Coimbra, TL
    Barros, VLRS
    Monath, TP
    Rodigues, SG
    Laval, C
    Costa, ZG
    Vilela, MFG
    Santos, CLS
    Papaiordanou, CMO
    Alves, VAF
    Andrade, LD
    Sato, HK
    Rosa, EST
    Froguas, GB
    Lacava, E
    Almeida, LMR
    Cruz, ACR
    Rocco, IM
    Santos, RTM
    Oliva, OFP
    [J]. LANCET, 2001, 358 (9276): : 91 - 97
  • [4] An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures
    Pereira, Renata C.
    Silva, Andrea N. M. R.
    Souza, Marta Cristina O.
    Silva, Marlon V.
    Neves, Patricia P. C. C.
    Silva, Andrea A. M. V.
    Matos, Denise D. C. S.
    Herrera, Miguel A. O.
    Yamamura, Anna M. Y.
    Freire, Marcos S.
    Gaspar, Luciane P.
    Caride, Elena
    [J]. VACCINE, 2015, 33 (35) : 4261 - 4268
  • [5] Duration of immunity in recipients of two doses of 17DD yellow fever vaccine
    Collaborative group for studies on yellow fever vaccines
    [J]. VACCINE, 2019, 37 (35) : 5129 - 5135
  • [6] MOLECULAR ANALYSIS OF YELLOW-FEVER VIRUS 17DD VACCINE STRAIN
    POST, PR
    SANTOS, CND
    CARVALHO, R
    LOPES, OS
    GALLER, R
    [J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1991, 86 (02): : 239 - 246
  • [7] Risk of fatal adverse events associated with 17DD yellow fever vaccine
    Struchiner, CJ
    Luz, PM
    Dourado, I
    Sato, HK
    Aguiar, SG
    Ribeiro, JGL
    Soares, RCR
    Codeço, TC
    [J]. EPIDEMIOLOGY AND INFECTION, 2004, 132 (05): : 939 - 946
  • [8] Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil
    Galler, R
    Pugachev, KV
    Santos, CLS
    Ocran, SW
    Jabor, AV
    Rodrigues, SG
    Marchevsky, RS
    Freire, MS
    Almeida, LFC
    Cruz, ACR
    Yamamura, AMY
    Rocco, IM
    da Rosa, EST
    Souza, LTM
    Vasconcelos, PFC
    Guirakhoo, F
    Monath, TP
    [J]. VIROLOGY, 2001, 290 (02) : 309 - 319
  • [9] Immune response induced by standard and fractional doses of 17DD yellow fever vaccine
    Abdala-Torres, Thais
    Campi-Azevedo, Ana Carolina
    da Silva-Pereira, Rosiane Aparecida
    dos Santos, Luara Isabela
    Henriques, Priscilla Miranda
    Costa-Rocha, Ismael Artur
    Otta, Dayane Andriotti
    Peruhype-Magalhaes, Vanessa
    Teixeira-Carvalho, Andrea
    Araujo, Marcio Sobreira Silva
    Fernandes, Eder Gatti
    Sato, Helena Keico
    Fantinato, Francieli Fontana Sutile Tardetti
    Domingues, Carla Magda Allan Santos
    Kallas, Esper Georges
    Tomiyama, Helena Tomoko Iwashita
    Lemos, Jandira Aparecida Campos
    Coelho-dos-Reis, Jordana Grazziela
    de Lima, Sheila Maria Barbosa
    Schwarcz, Waleska Dias
    Azevedo, Adriana de Souza
    Trindade, Gisela Freitas
    Bom, Ana Paula Dinis Ano
    da Silva, Andrea Marques Vieira
    Fernandes, Camilla Bayma
    Camacho, Luiz Antonio Bastos
    Maia, Maria de Lourdes de Sousa
    Martins-Filho, Olindo Assis
    do Antonelli, Lis Ribeiro do Valle
    [J]. NPJ VACCINES, 2024, 9 (01)
  • [10] EFFECTS AND SAFETY OF THE YELLOW FEVER VACCINE 17DD IN PATIENTS WITH IMMUNOMEDIATED RHEUMATIC DISEASES
    Bica, Blanca
    Da Silva, Lucas Peixoto
    Pileggi, Gecilmara Salviato
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 2059 - 2060